WO2013039094A1 - アミノ酸の製造法 - Google Patents
アミノ酸の製造法 Download PDFInfo
- Publication number
- WO2013039094A1 WO2013039094A1 PCT/JP2012/073294 JP2012073294W WO2013039094A1 WO 2013039094 A1 WO2013039094 A1 WO 2013039094A1 JP 2012073294 W JP2012073294 W JP 2012073294W WO 2013039094 A1 WO2013039094 A1 WO 2013039094A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- valine
- glutamic acid
- aqueous solution
- granules
- amino acid
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
Definitions
- the present invention relates to a method for granulating L-valine.
- the amino acid accumulated in the culture is usually recovered as a solid.
- a crude purified solution is prepared by removing impurities by passing through a resin tower or the like, and the solution is concentrated to crystallize the amino acid. And then separating the solution and the crystal (hereinafter referred to as solid-liquid separation) to recover the amino acid as a crystal.
- flake-like and fine powder crystals have a bad influence on the quality of the product and the production cost, such as poor solid-liquid separation performance due to their shapes, and longer crystal drying time.
- the flake-like or fine-powder crystal as described above has a small specific gravity and a high bulk, so that the amount entering a fixed volume container is small and not only inefficient in transportation, but also the final product. There is also a possibility that the usage amount will be limited.
- Patent Document 1 discloses that when adding a seed crystal of the target amino acid to crystallize the amino acid crystal, the size of the precipitated amino acid crystal can be controlled by adjusting the grain size and concentration of the seed crystal. Has been.
- Non-Patent Document 1 discloses that the crystal appearance of L-isoleucine changes with the addition of L-alanine, and that L-isoleucine granules can be obtained depending on the amount of L-alanine added.
- L-valine granules can be obtained by adding L-glutamic acid to an aqueous solution containing L-valine.
- L-valine is purified as a granule.
- L-valine with improved solid-liquid separation and high specific gravity can be obtained by granulation.
- the present invention relates to the methods described in the following (1) to (4).
- (1) After adding 0.5% by weight or more of L-glutamic acid to L-valine and dissolving it in an aqueous solution containing L-valine, the pH of the aqueous solution is adjusted to acidic, and then L-valine is crystallized.
- a process for producing L-valine granules characterized in that (2) The process according to (1) above, wherein the acidity is pH 3.0 to 6.0. (3) The production method of (1) or (2) above, wherein the crystallization is crystallization by concentration under reduced pressure.
- (4) The process according to any one of (1) to (3) above, wherein the concentration of L-valine in the aqueous solution containing L-valine is 20 g / L or more.
- L-valine granules can be produced efficiently.
- FIG. 3 is a diagram showing the shape of L-valine granules depending on the amount of L-glutamic acid added.
- A No L-glutamic acid added,
- B 0.5% by weight of L-glutamic acid with respect to L-valine,
- c 2.0% by weight,
- d 4.0% by weight, respectively.
- the granule shape of L-valine is shown.
- L-glutamic acid with respect to L-valine is added to and dissolved in an aqueous solution containing L-valine, and then the pH of the solution is adjusted to acidity. It is a method for producing L-valine granules characterized by crystallizing valine.
- the L-valine granule in the present invention has an average particle size of 100 ⁇ m or more, preferably 200 ⁇ m or more, 3 mm or less, more preferably 250 ⁇ m or more, 2 mm or less, when the particle size of a plurality of granules is measured under a microscope. More preferable examples include L-valine granules of 500 ⁇ m or more and 1 mm or less.
- An aqueous solution containing L-valine can be prepared by a fermentation method in which a microorganism having the ability to produce L-valine is cultured in a medium, and L-valine is produced and accumulated in the culture. It is not limited, For example, what was prepared by the synthesis method may be used.
- the aqueous solution containing L-valine prepared by the fermentation method may be an aqueous solution in which insoluble matter such as cells in the culture is removed by centrifugation, membrane treatment, or the like. It may be an aqueous solution containing L-valine purified by use.
- the concentration of L-valine in the aqueous solution containing L-valine may be any concentration as long as L-valine is granulated by adding glutamic acid and performing a crystallization operation.
- L-glutamic acid is 0.5% by weight or more, preferably 1.0% by weight or more and 6.0% by weight or less, more preferably 1.5% by weight or more and 5.0% by weight or less, further preferably 2.0% by weight or more, 4.0% by weight or more with respect to L-valine.
- L-valine It is added to an aqueous solution containing L-valine so as to be not more than wt%.
- concentration of L-glutamic acid in the solution is higher, the size of L-valine granules obtained by the subsequent crystallization operation becomes larger, but at the same time, L-glutamic acid crystallized by the crystallization operation also increases.
- the amount of L-glutamic acid added can be controlled in accordance with the allowable mixing amount of L-glutamic acid.
- the L-glutamic acid to be added may be a solid or an L-glutamic acid aqueous solution.
- L-glutamic acid When L-glutamic acid is added, if necessary to dissolve L-valine or L-glutamic acid in the solution, the solution may be heated.
- L-glutamic acid When L-glutamic acid is added to an aqueous solution of L-valine, it is preferably added with stirring.
- the pH of the aqueous solution is preferably adjusted to be acidic, specifically, 3.0 to 6.0, preferably 3.5 to 5.0, more preferably about 4.0.
- acidic specifically, 3.0 to 6.0, preferably 3.5 to 5.0, more preferably about 4.0.
- sulfuric acid can be used.
- a crystallization operation is performed to form L-valine granules. Crystallization can be carried out by any known method, such as adding an organic solution such as ethanol or butanol, or cooling the aqueous solution, as long as L-valine granules can be obtained. However, crystallization by vacuum concentration is preferable.
- the resulting concentrated solution is at a constant temperature, such as 10 to 30 ° C., preferably 15 to 25 ° C., more preferably about 25 ° C. for 30 minutes to 15 hours, preferably 1 to 10 hours, more preferably By keeping it for 2 to 8 hours, the granules can be aged.
- L-valine granules can be obtained by solid-liquid separation of the concentrate containing the granules by an operation such as centrifugation.
- the impurities attached to the surface may be removed by washing the granules obtained by separation with an aqueous solution or the like.
- L-valine granules by adding L-glutamic acid
- aqueous solution 99.0% purity L-valine manufactured by Kyowa Hakko Bio Inc. dissolved in 100 mL distilled water
- L-glutamic acid, L-alanine, or L-arginic acid all 99.0% purity amino acid manufactured by Kyowa Hakko Bio Co., Ltd.
- the obtained amino acid was stirred while being kept at 60 ° C. until it completely dissolved. Thereafter, the aqueous solution was gradually cooled to 30 ° C.
- each solution was adjusted to 4.0 by adding sulfuric acid or 5 mol / L sodium hydroxide to the aqueous solution.
- the glass container was sealed, the temperature was raised to 80 ° C., and the pressure was reduced to perform concentration under reduced pressure.
- the aqueous solution concentrated under reduced pressure was rapidly cooled to 25 ° C. and left at that temperature for 5 hours.
- L-glutamic acid was added, L-valine granules were formed, but in the solution to which other amino acids were added, L-valine could only be obtained as microcrystals.
- the method of the present invention makes it possible to industrially produce easy-to-handle L-valine granules.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
(1)L-バリンを含有する水溶液に、L-バリンに対して0.5重量%以上のL-グルタミン酸を添加して溶解させた後、水溶液のpHを酸性に調整し、その後L-バリンを晶析させることを特徴とするL-バリン顆粒の製造法。
(2)酸性が、pHが3.0~6.0であることを特徴とする上記(1)の製造法。
(3)晶析が、減圧濃縮による晶析である上記(1)または(2)の製造法。
(4)L-バリンを含有する水溶液のL-バリン濃度が、20g/L以上である上記(1)~(3)のいずれか1つの製造法。
本発明におけるL-バリン顆粒とは、顕微鏡下で複数個の顆粒の粒径を測定したとき、その平均粒径が100μm以上、好ましくは200μm以上、3mm以下、より好ましくは250μm以上、2mm以下、さらに好ましくは500μm以上、1mm以下のL-バリン顆粒をあげることができる。
L-グルタミン酸は、L-バリンに対して0.5重量%以上、好ましくは1.0重量%以上、6.0重量%以下、より好ましくは1.5重量%以上、5.0重量%以下、さらに好ましくは2.0重量%以上、4.0重量%以下になるようにL-バリンを含有する水溶液に添加する。溶液中のL-グルタミン酸の濃度が高い方が、その後の晶析操作で得られるL-バリン顆粒の大きさはより大きくなるが、同時に晶析操作で晶析するL-グルタミン酸も増加するので、L-バリン顆粒に混入するL-グルタミン酸を少なくしたい場合は、L-グルタミン酸の混入許容量に合わせて添加するL-グルタミン酸量をコントロールすることができる。
L-バリンの水溶液にL-グルタミン酸を添加する際は、攪拌しながら添加するのが好ましい。
pHを調整した後、晶析操作を行うことによりL-バリンの顆粒を形成させる。晶析は、一般に知られている晶析方法、例えばエタノール、ブタノール等の有機溶液を添加する方法、水溶液を冷却する方法など、L-バリン顆粒が得られる方法であれば、いずれの方法であってもよいが、減圧濃縮による晶析が好ましい。
顆粒を含む濃縮液を遠心分離等の操作により固液分離することにより、L-バリンの顆粒を得ることができる。
50g/LのL-バリン水溶液100mL(協和発酵バイオ社製の純度99.0%のL-バリンを100mLの蒸留水に溶解)が入った1000mLのガラス容器に、L-グルタミン酸、L-アラニン、またはL-アルギニン酸(いずれも協和発酵バイオ社製の純度99.0%のアミノ酸)をL-バリンに対して2.0重量%の濃度で添加し、L-バリンおよび添加したアミノ酸が完全に溶解するまで60℃に保ちながら攪拌した。その後、30℃になるまで徐々に水溶液を冷却した。
次に、ガラス容器を密閉し、温度を80℃に上げ、かつ減圧することにより減圧濃縮を行った。減圧濃縮した水溶液は25℃に急速冷却し、その温度で5時間放置した。
その結果、L-グルタミン酸を添加した溶液では、L-バリンの顆粒が形成されたが、他のアミノ酸を添加した溶液ではL-バリンは微小結晶としてしか得ることはできなかった。
L-グルタミン酸、L-アラニン、またはL-アルギニン酸を加える代わりに、アミノ酸無添加、およびL-グルタミン酸を0.5、2.0または4.0重量%になるようにL-バリン水溶液に加えた以外は、実施例1と同様の操作を行った。
その結果、図1に示すように、顕微鏡(キーエンス Digital microscope VHX-900)で顆粒形成の有無を確認したところ、L-グルタミン酸を0.5重量%以上の濃度になるように添加した場合、L-バリンが顆粒化することが確認された。
L-グルタミン酸、L-アラニン、またはL-アルギニン酸を加える代わりに、アミノ酸としてはL-グルタミン酸のみを添加し、その後水溶液のpHを4.0、7.0、または10.0に調整した以外は、実施例1と同様に操作を行った。
その結果、pH4.0では顆粒が形成されたが、pH7.0及び10.0では顆粒が形成されず、L-バリンの微結晶が生成しただけであった。
Claims (4)
- L-バリンを含有する水溶液に、L-バリンに対して0.5重量%以上のL-グルタミン酸を添加して溶解させた後、水溶液のpHを酸性に調整し、その後L-バリンを晶析させることを特徴とするL-バリン顆粒の製造法。
- 酸性が、pHが3.0~6.0であることを特徴とする請求項1の製造法。
- L-バリンの晶析が、減圧濃縮による晶析である請求項1または2の製造法。
- L-バリンを含有する水溶液のL-バリン濃度が、20g/L以上である請求項1~3のいずれか一項に記載の製造法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12831082.8A EP2757089B1 (en) | 2011-09-12 | 2012-09-12 | Production method for amino acid |
BR112014005784-2A BR112014005784B1 (pt) | 2011-09-12 | 2012-09-12 | Processo para a produção de aminoácidos |
JP2013533684A JP6047095B2 (ja) | 2011-09-12 | 2012-09-12 | アミノ酸の製造法 |
CN201280044497.6A CN103889946B (zh) | 2011-09-12 | 2012-09-12 | 制造氨基酸的方法 |
US14/343,964 US9227916B2 (en) | 2011-09-12 | 2012-09-12 | Process for producing amino acid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011198785 | 2011-09-12 | ||
JP2011-198785 | 2011-09-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013039094A1 true WO2013039094A1 (ja) | 2013-03-21 |
Family
ID=47883319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/073294 WO2013039094A1 (ja) | 2011-09-12 | 2012-09-12 | アミノ酸の製造法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9227916B2 (ja) |
EP (1) | EP2757089B1 (ja) |
JP (1) | JP6047095B2 (ja) |
CN (1) | CN103889946B (ja) |
BR (1) | BR112014005784B1 (ja) |
WO (1) | WO2013039094A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113773215A (zh) * | 2020-06-10 | 2021-12-10 | 安徽华恒生物科技股份有限公司 | 一种高堆积密度的l-缬氨酸及其制备方法和其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018190398A1 (ja) * | 2017-04-13 | 2018-10-18 | 協和発酵バイオ株式会社 | テアニンの製造方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6357560A (ja) * | 1986-08-29 | 1988-03-12 | Hiroyuki Nohira | Dl−バリンの光学分割法 |
JPH08333312A (ja) * | 1995-06-12 | 1996-12-17 | Ajinomoto Co Inc | バリンの精製法 |
WO2006109830A1 (ja) | 2005-04-12 | 2006-10-19 | Kyowa Hakko Kogyo Co., Ltd. | アミノ酸の製造法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3445932A1 (de) * | 1984-12-17 | 1986-06-26 | Boehringer Ingelheim KG, 6507 Ingelheim | Pharmazeutische zusammensetzungen |
JPH0617344B2 (ja) * | 1986-04-28 | 1994-03-09 | 味の素株式会社 | バリンの分離精製法 |
JP2744648B2 (ja) * | 1989-06-29 | 1998-04-28 | 協和醗酵工業株式会社 | アミノ酸顆粒の製造法 |
JPH1059911A (ja) * | 1996-08-16 | 1998-03-03 | Ajinomoto Co Inc | 酸性アミノ酸の晶析方法 |
JPWO2010050168A1 (ja) * | 2008-10-27 | 2012-03-29 | 味の素株式会社 | バリン、イソロイシン、ロイシン固溶体およびその製造方法 |
-
2012
- 2012-09-12 US US14/343,964 patent/US9227916B2/en active Active
- 2012-09-12 WO PCT/JP2012/073294 patent/WO2013039094A1/ja active Application Filing
- 2012-09-12 BR BR112014005784-2A patent/BR112014005784B1/pt active IP Right Grant
- 2012-09-12 JP JP2013533684A patent/JP6047095B2/ja active Active
- 2012-09-12 EP EP12831082.8A patent/EP2757089B1/en active Active
- 2012-09-12 CN CN201280044497.6A patent/CN103889946B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6357560A (ja) * | 1986-08-29 | 1988-03-12 | Hiroyuki Nohira | Dl−バリンの光学分割法 |
JPH08333312A (ja) * | 1995-06-12 | 1996-12-17 | Ajinomoto Co Inc | バリンの精製法 |
WO2006109830A1 (ja) | 2005-04-12 | 2006-10-19 | Kyowa Hakko Kogyo Co., Ltd. | アミノ酸の製造法 |
Non-Patent Citations (3)
Title |
---|
J CHEM. ENG.. DATA, vol. 53, 2008, pages 2801 - 2806 |
See also references of EP2757089A4 * |
T.KAMEI ET AL.: "Solid-Liquid Equilibria in an L-Isoleucine + L-Alanine + Water System", JOURNAL OF CHEMICAL & ENGINEERING DATA, vol. 53, no. 12, 2008, pages 2801 - 2806, XP055144714 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113773215A (zh) * | 2020-06-10 | 2021-12-10 | 安徽华恒生物科技股份有限公司 | 一种高堆积密度的l-缬氨酸及其制备方法和其应用 |
CN113773215B (zh) * | 2020-06-10 | 2024-02-02 | 安徽华恒生物科技股份有限公司 | 一种高堆积密度的l-缬氨酸及其制备方法和其应用 |
Also Published As
Publication number | Publication date |
---|---|
BR112014005784A2 (pt) | 2017-03-28 |
EP2757089A1 (en) | 2014-07-23 |
BR112014005784B1 (pt) | 2019-07-16 |
CN103889946A (zh) | 2014-06-25 |
US9227916B2 (en) | 2016-01-05 |
US20140228593A1 (en) | 2014-08-14 |
JPWO2013039094A1 (ja) | 2015-03-26 |
JP6047095B2 (ja) | 2016-12-21 |
CN103889946B (zh) | 2015-06-03 |
EP2757089A4 (en) | 2015-05-27 |
EP2757089B1 (en) | 2016-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014501116A5 (ja) | ||
CN105254520A (zh) | 酶法合成阿莫西林结晶母液中d-对羟基苯甘氨酸的回收方法 | |
CN110776543A (zh) | 一种腺苷一次母液回收方法 | |
JP6047095B2 (ja) | アミノ酸の製造法 | |
JP2015500643A (ja) | 動物飼料のためのメチオニン化合物 | |
JP2016101170A (ja) | 発酵液から1,4−ジアミノブタンを分離及び精製する方法 | |
CN101100437B (zh) | 一种β-丙氨酸的纯化方法 | |
CN110922417B (zh) | 一种头孢氨苄结晶母液回收方法 | |
US8137939B2 (en) | Method of recovering L-threonine from L-threonine fermentation broth using nonsolvent | |
CN105753728A (zh) | 一种药用级l-缬氨酸的溶析结晶方法 | |
CN110885357B (zh) | 一种纳滤膜分离纯化丙谷二肽的方法 | |
KR20180093981A (ko) | 발효적 생산에 의해 l-메티오닌을 생산하는 방법 | |
CN108558908B (zh) | 一种头孢他啶母液的除盐方法及头孢他啶的制备方法 | |
CN101643400B (zh) | 一种从发酵液中提取丁二酸的方法 | |
US20230416197A1 (en) | High-efficiency cyclic preparation method for columnar taurine | |
JP2004298106A (ja) | D−アロースの結晶化法による分別法とその大量生産への応用 | |
CN116410099A (zh) | 从d-天冬氨酸母液中回收l-丙氨酸的方法 | |
CN103450300B (zh) | 一种咪唑立宾的提纯方法 | |
CA2992676A1 (en) | Method for providing a succinic acid solution | |
CN106674037A (zh) | 一种从阿巴斯甜合成母液中分离l‑苯丙氨酸的方法 | |
CN103626840A (zh) | 一种原料含有手性异构体的阿斯巴甜的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12831082 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013533684 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2012831082 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012831082 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14343964 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014005784 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014005784 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140312 |